Pediatric Praziquantel Consortium

Pediatric Praziquantel Consortium successfully completed Phase II in Ivory Coast

10 December 2018

The important milestone of Last Patient Last Visit (LPLV) in the clinical Phase II trial was achieved on...

Astellas Global Health Foundation Launches

29 November 2018

On 20 November 2018, Astellas Pharma Inc. announced the launch of the Astellas Global Health Foundation (AGHF): a...

A story of schistosomiasis infection in Ghana

A story of schistosomiasis infection in Ghana.
Video credit: Shelly Xie

Vision

Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more

Mission

Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development program

Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.

Read more

The pediatric formulation

A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. The formulation is a small, orally dispersible tablet with an acceptable taste.

Read more